Point72 Asset Management
TXMD icon

Point72 Asset Management’s TherapeuticsMD TXMD Stock Holding History

Point72 Asset Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5,652
Closed -$1.5M – 1087
2017
Q3 		$1.5M Sell
5,652
-9,688
-63% -$2.8M 0.01% 705
2017
Q2 		$4.04M Buy
15,340
+9,406
+159% +$2.36M 0.02% 544
2017
Q1 		$2.14M Buy
5,934
+1,868
+46% +$578K 0.01% 665
2016
Q4 		$1.17M Buy
+4,066
New +$1.26M 0.01% 597

Other funds holding TXMD

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Point72 Asset Management's TXMD Position: Q4 2017 in Review

Point72 Asset Management sold out of TherapeuticsMD (TXMD) in Q4 2017, closing a stake of 5,652 shares — an estimated $1.5M sold.

Point72 Asset Management first reported a position in TXMD in Q4 2016 and held it in 4 quarters. The position peaked at $4.04M in Q2 2017. 144 funds tracked by Wall St. Rank hold TXMD as of Q4 2017.

  • Point72 Asset Management reported no remaining TherapeuticsMD position as of Q4 2017 after selling out during the quarter.
  • Point72 Asset Management sold 5,652 TherapeuticsMD shares in Q4 2017, an estimated $1.5M.
  • Point72 Asset Management first reported a position in TherapeuticsMD in Q4 2016 and held it in 4 quarters.
  • Point72 Asset Management's TherapeuticsMD position peaked at $4.04M in Q2 2017.
  • 144 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2017.

Based on Point72 Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.